The patent application — 2003-532675 — is owned by the Max Planck Institute, but is exclusively licensed to miRNA drug developer and Alnylam/Isis joint venture Regulus Therapeutics.
The application, No. 20060058266, is entitled "Chemically modified oligonucleotides," and claims "composition and methods for making and using chemically modified oligonucleotide agents for inhibiting gene expression," according to its abstract.
MDRNA, Roche, Arrowhead Research, Rosetta Genomics, Alnylam Pharmaceuticals, Genesis Research and Development
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.